NCT07012447View on ClinicalTrials.gov

Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

May 1, 2028

Conditions
Early T Acute Lymphoblastic LeukemiaT-Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia, T/Myeloid, Nos
Interventions
DRUG

Venetoclax

Orally by mouth

DRUG

Azacitidine

Subcutaneous injection

DRUG

Cytarabine

Intravenous infusion

Trial Locations (1)

215006

RECRUITING

Ethical Committee of the First Affliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

yuejun Liu

OTHER